In EGFR-mutated NSCLC, targeted GFPT2 inhibition restores anti-tumor immunity by enhancing CD8 + T cell infiltration and reducing immune checkpoint activity [166]. Here, GFPT2 is linked to non-small cell lung carcinoma.